# ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA

> **NCT05992142** · PHASE4 · COMPLETED · sponsor: **Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW** · enrollment: 200 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** 5-ASA

## Key facts

- **NCT ID:** NCT05992142
- **Lead sponsor:** Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-17
- **Primary completion:** 2024-02-01
- **Final completion:** 2024-02-01
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2024-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05992142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05992142, "ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05992142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*